Advisors Asset Management Inc. Purchased Shares of 570,352 Mazor Robotics Ltd – (MZOR)

Advisors Asset Management Inc. Purchased Shares of 570,352 Mazor Robotics Ltd – (MZOR)

Advisors Asset Management Inc. bought a new position in Mazor Robotics Ltd – (NASDAQ:MZOR) in the 2nd quarter, HoldingsChannel reports. The fund bought 570,352 shares of the medical instruments supplier’s stock, valued at approximately $451,000.

Other institutional investors have also recently modified their holdings of the company. Natixis boosted its holdings in Mazor Robotics by 7.4% in the 2nd quarter. Natixis now owns 57,273 shares of the medical instruments supplier’s stock worth $3,179,000 after buying an additional 3,953 shares during the period. First Allied Advisory Services Inc. boosted its holdings in Mazor Robotics by 217.2% in the 2nd quarter. First Allied Advisory Services Inc. now owns 14,562 shares of the medical instruments supplier’s stock worth $806,000 after buying an additional 9,971 shares during the period. Marshall Wace LLP bought a new position in Mazor Robotics in the 2nd quarter worth $240,000. Alps Advisors Inc. bought a new position in Mazor Robotics in the 2nd quarter worth $279,000. Finally, Dorsey Wright & Associates boosted its holdings in shares of Mazor Robotics by 16.9% during the 2nd quarter. Dorsey Wright & Associates now owns 192,549 shares of the medical instruments supplier’s stock valued at $10,648,000 after purchasing an additional 27,809 shares during the last quarter. 23.98% of the stock is owned by institutional investors.

Shares of NASDAQ MZOR opened at $57.98 on Wednesday. The stock has a market cap of $1.54 billion, a PE ratio of -115.96 and a beta of 1.43. Mazor Robotics Ltd – has a 12-month low of $41.60 and a 12-month high of $76.56.

Mazor Robotics (NASDAQ:MZOR) last announced its earnings results on Thursday, August 2nd. The medical instruments supplier reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.13). The business had revenue of $13.20 million for the quarter, compared to analysts’ expectations of $17.02 million. Mazor Robotics had a negative net margin of 12.80% and a negative return on equity of 7.17%. The firm’s quarterly revenue was down 14.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.05) earnings per share. As a group, sell-side analysts anticipate that Mazor Robotics Ltd – will post -0.12 earnings per share for the current fiscal year.

Several research analysts have commented on the stock. Zacks Investment Research raised shares of Mazor Robotics from a “sell” rating to a “hold” rating in a report on Friday, September 28th. BidaskClub raised shares of Mazor Robotics from a “hold” rating to a “buy” rating in a report on Saturday, September 22nd. Needham & Company LLC raised shares of Mazor Robotics from an “underperform” rating to a “hold” rating in a report on Friday, September 21st. Finally, ValuEngine raised shares of Mazor Robotics from a “hold” rating to a “buy” rating in a report on Friday, September 7th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. Mazor Robotics has a consensus rating of “Hold” and a consensus target price of $61.08.

About Mazor Robotics

Mazor Robotics Ltd., together with its subsidiaries, engages in the development, production, and marketing of medical devices for supporting surgical procedures in the fields of orthopedics and neurosurgery in the United States and internationally. It operates in the field of computer assisted surgery that enable the use of surgical instruments with high precision and minimal invasiveness and that simplifies complex surgical procedures.

Further Reading: Penny Stocks, What You Need To Know

Want to see what other hedge funds are holding MZOR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mazor Robotics Ltd – (NASDAQ:MZOR).

Related posts

Leave a Comment